Lupin Pharmaceuticals has received approval for its Irbesartan tablets, used for treating hypertension, from US Food and Drugs Administration (USFDA).
The tablets are available in 75-300 mg strengths and are the AB-rated generic equivalent of Sanofi Aventis's Avapro tablets, Lupin said in a statement issued here.
Irbesartan is indicated for the treatment of hypertension and nephropathy in type II diabetic patients, it added.
Avapro tablets had annual US sales of about $400.7 million in June, as per the IMS health sales data.
Lupin is the fifth largest generic player in the US with 5.1% market share by prescriptions.
The company said it is also the fastest growing, top 10 pharma player in India, Japan and South Africa.
